Usefulness of chemotherapy as prophylaxis of tumor recurrence after liver transplantation in advanced hepatocellular carcinomas

被引:12
|
作者
De la Revilla, NJ [1 ]
Moreno, JM [1 ]
Rubio, E [1 ]
de Herreros, TA [1 ]
Navarrete, E [1 ]
Lopez, MJ [1 ]
Turrion, VS [1 ]
Jimenez, M [1 ]
Lucena, M [1 ]
Cuervas-Mons, V [1 ]
机构
[1] Univ Autonoma Madrid, Hosp Univ Puerta Hierro, Liver Transplantat Unit, Madrid, Spain
关键词
D O I
10.1016/S0041-1345(03)00583-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction. The effectiveness of chemotherapy as prophylaxis of tumor recurrence after liver transplantation in patients with advanced hepatocellular carcinoma is controversial Aim. Our goal was to assess the outcomes of patients with advanced hepatocellular carcinoma treated with chemotherapy after liver transplant. Methods. Ten patients with liver transplants performed between 1993-2002 were men of mean age 55 years. The etiology of cirrhosis was hepatitis C in four patients, alcoholic cirrhosis in four, and cryptogenic cirrhosis in two. Immunosuppressive therapy was cyclosporine in five patients and tacrolimus in five. The chemotherapy regimen used adriamycin (20 mg/m(2) weekly for 20 weeks). Six patients were stage IVA and four stage III. Hepatocellular carcinoma was known in five patients and incidental in the other five. Pathology revealed well-differentiated hepatocellular carcinoma in six patients and moderately differentiated hepatocellular carcinoma in four. Five patients had vascular invasion. Results. After a mean posttransplant follow-up of 28 months, six patients (60%) were alive without tumor recurrence, three (30%) had died from tumor recurrence and one due to P. carinii pneumonia. Disease-free survival among patients with stage III was 50% and 80% for stage IVA. Three patients with vascular invasion died of tumor recurrence, and the other two are alive and free of disease. Disease-free survival rates were 83% in patients with well-differentiated hepatocellular carcinoma and 25% in those with moderately differentiated hepatocellular carcinoma. Tolerance of chemotherapy was good with two withdrawals due to nephrotoxicity and myelotoxicity and one death from pneumonia. Conclusion. The use of adriamycin in patients undergoing liver transplant due to advanced hepatocellular carcinoma may be useful to prevent tumor recurrence; it is well tolerated. The presence of vascular tumor invasion and a lower grade of histologic differentiation were associated with a poor prognosis.
引用
收藏
页码:1830 / 1831
页数:2
相关论文
共 50 条
  • [1] TUMOR RECURRENCE PREDICTS HBV RECURRENCE AFTER LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA
    Kim, Seong Hoon
    Kim, Young-Kyu
    Lee, Seung Duk
    Han, Sung-Sik
    Park, Sang-Jae
    TRANSPLANT INTERNATIONAL, 2013, 26 : 293 - 293
  • [2] Tumor recurrence after liver transplantation for hepatocellular carcinoma:: Recurrence pathway and prognostic factors
    Perez-Saborido, B.
    Galanes, S. Jimenez de los
    Meneu-Diaz, J. C.
    Romero, C. Jimenez
    Elola-Olaso, A. Moreno
    Suarez, Y. Funclora
    Valencia, V. Barra
    Moreno-Gonzalez, E.
    TRANSPLANTATION PROCEEDINGS, 2007, 39 (07) : 2304 - 2307
  • [3] TUMOR RECURRENCE AFTER LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA. RECURRENCE PATHWAYS AND TREATMENT
    Perez-Saborido, Baltasar
    Donat-Garrido, Maria
    Barra-Valencia, Vanessa
    Gimeno-Calvo, Alberto
    Jimenez de Los Galanes-Marchan, Santos
    Moreno Elola-Olaso, Almudena
    Fundora-Suarez, Yillian
    Carlos Meneu-Diaz, Juan
    Abradelo de Usera, Manuel
    Lopez-Jara, Vanesa
    Moreno-Gonzalez, Enrique
    TRANSPLANT INTERNATIONAL, 2009, 22 : 217 - 217
  • [4] Tumor recurrence after liver transplantation for hepatocellular carcinoma: Recurrence pathway and prognostic factors
    Perez-Saborido, Baltasar
    Jimenez-Galanes Marchan, Santos
    Carlos Meneu-Djaz, Juan
    Jimenez-Romero, Carlos
    Elola-Olaso, Almudena
    Fundora Suarez, Yiliam
    Barra Valencia, Vanessa
    Abradelo de Usera, Manuel
    Gimeno Calvo, Alberto
    Moreno-Gonzalez, Enrique
    TRANSPLANT INTERNATIONAL, 2008, 21 : 9 - 9
  • [5] The Chemotherapy Effects on Tumor Recurrence after Liver Transplantation under Different Liver Transplantation Criteria
    Wei, L.
    TRANSPLANTATION, 2017, 101 (05) : 225 - 225
  • [6] The impact of rituximab prophylaxis on hepatocellular carcinoma recurrence after living donor liver transplantation
    Kamo, Naoko
    Yagi, Shintaro
    HEPATOMA RESEARCH, 2021, 7
  • [7] Hepatocellular Carcinoma Recurrence After Liver Transplantation
    Gabutti, Alejandro
    Bhoori, Sherrie
    Cascella, Tommaso
    Bongini, Marco
    ONCOLOGY-NEW YORK, 2020, 34 (03): : 91 - 94
  • [8] PREDICTIVE VALUE OF TUMOR MARKER ON HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION
    Choi, Gi H.
    Kim, Myoung S.
    Kim, Soon I.
    Lee, Hyung S.
    TRANSPLANT INTERNATIONAL, 2013, 26 : 85 - 85
  • [9] Recurrence of hepatocellular carcinoma after liver transplantation
    Escartin, A.
    Sapisochin, G.
    Bilbao, I.
    Vilallonga, R.
    Bueno, J.
    Castells, L.
    Dopazo, C.
    Castro, E.
    Caralt, M.
    Balsells, J.
    TRANSPLANTATION PROCEEDINGS, 2007, 39 (07) : 2308 - 2310
  • [10] Role of selected criteria and preventive chemotherapy in tumor recurrence after liver transplantation
    Mei-Xi Wang
    Dong Chen
    Yuan-Yuan Zhao
    Bo Yang
    Ji-Pin Jiang
    Fan-Jun Zeng
    Lai Wei
    Zhi-Shui Chen
    Hepatobiliary & Pancreatic Diseases International, 2020, 19 (04) : 378 - 383